Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
Authors
Keywords
-
Journal
Vaccines
Volume 9, Issue 8, Pages 914
Publisher
MDPI AG
Online
2021-08-18
DOI
10.3390/vaccines9080914
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fast-spreading COVID variant can elude immune responses
- (2021) Ewen Callaway NATURE
- A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
- (2021) Abigail E. Powell et al. ACS Central Science
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- How ‘killer’ T cells could boost COVID immunity in face of new variants
- (2021) Heidi Ledford NATURE
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes
- (2021) Mayank Batra et al. Scientific Reports
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
- (2021) Alona Kuzmina et al. Cell Host & Microbe
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- (2021) Kevin O. Saunders et al. NATURE
- The race for antiviral drugs to beat COVID — and the next pandemic
- (2021) Elie Dolgin NATURE
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
- (2021) Sisi Kang et al. Nature Communications
- Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
- (2021) Bradley A Connor et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
- (2021) Yuxin Chen et al. LANCET INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
- (2021) Markus Hoffmann et al. Cell Reports
- A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials
- (2021) Jeyanthi Venkadapathi et al. Frontiers in Molecular Biosciences
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)
- (2020) Dae-Gyun Ahn et al. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
- Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1β/Neutrophil Extracellular Traps feedback loop
- (2020) Ahmed Yaqinuddin et al. MEDICAL HYPOTHESES
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- (2020) Kai Duan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- (2020) Bette Korber et al. CELL
- COVID-19 vaccine development and a potential nanomaterial path forward
- (2020) Matthew D. Shin et al. Nature Nanotechnology
- Vaccines for COVID-19: The current state of play
- (2020) Archana Koirala et al. Paediatric Respiratory Reviews
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
- (2020) Shuo Du et al. CELL
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
- (2020) Ahmed O. Hassan et al. CELL
- Spike mutation D614G alters SARS-CoV-2 fitness
- (2020) Jessica A. Plante et al. NATURE
- COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment
- (2020) Anant Parasher POSTGRADUATE MEDICAL JOURNAL
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
- (2020) Mimi Guebre-Xabier et al. VACCINE
- A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone
- (2020) Baoshan Zhang et al. Scientific Reports
- Role of monoclonal antibody drugs in the treatment of COVID-19
- (2020) Claudio Ucciferri et al. World Journal of Clinical Cases
- Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
- (2020) Sören Reinke et al. Vaccines
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- Developments in the formulation and delivery of spray dried vaccines
- (2017) Gaurav Kanojia et al. Human Vaccines & Immunotherapeutics
- Theory, simulations and the design of functionalized nanoparticles for biomedical applications: A Soft Matter Perspective
- (2017) Stefano Angioletti-Uberti npj Computational Materials
- Engineering virus-like particles as vaccine platforms
- (2016) Kathryn M Frietze et al. Current Opinion in Virology
- Nanostructures for protein drug delivery
- (2016) Juliana de Almeida Pachioni-Vasconcelos et al. Biomaterials Science
- Biomaterials for Nanoparticle Vaccine Delivery Systems
- (2014) Preety Sahdev et al. PHARMACEUTICAL RESEARCH
- The Coronavirus Nucleocapsid Is a Multifunctional Protein
- (2014) Ruth McBride et al. Viruses-Basel
- Mucosal immunization provides better protection than subcutaneous immunization against Pasteurella multocida (B:2) in mice preimmunized with the outer membrane proteins
- (2011) Subhash Kharb et al. VETERINARY RESEARCH COMMUNICATIONS
- Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies
- (2009) J. W. Mapletoft et al. Clinical and Vaccine Immunology
- PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants
- (2009) Takeshi Ichinohe et al. VACCINE
- Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
- (2009) Stacey L. Demento et al. VACCINE
- Nanoparticle vaccines against respiratory viruses
- (2009) Brian M. Adair Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started